{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000092","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.728511+00:00","generated_at":"2026-05-16T13:15:12.649530+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"AEON Biopharma signs definitive exchange with Daewoong; $15M notes swapped for equity, new $1.5M note due 2030","bullets":["Exchange eliminates >90% of AEON's outstanding debt; Daewoong receives ~23.1M shares, $1.5M new convertible note at 15.79% due Apr 2030.","Daewoong gets cash-exercise warrant for 8M shares at $1.09392/share, representing up to $8M+ potential proceeds for AEON.","Exchange remains subject to stockholder vote; closing expected after vote on Jan 21, 2026.","Daewoong will nominate Seongsoo Park as Class III director at 2026 annual meeting; Park currently on board."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000092","json":"https://secwatch.observer/filing/0001837607-25-000092.json","markdown":"https://secwatch.observer/filing/0001837607-25-000092.md","text":"https://secwatch.observer/filing/0001837607-25-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000092/0001837607-25-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000092/aeon-20251215x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:15:12.649530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}